

Jynarque® (tolvaptan) - First-time generic

- On May 13, 2025, <u>Lupin launched</u> an <u>AB-rated</u> generic version of Otsuka's <u>Jynarque (tolvaptan)</u> tablets.
 - Lupin was granted 180-days of generic exclusivity for its generic Jynarque.
- Jynarque is approved to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease.
- Jynarque carries a boxed warning for risk of serious liver injury.
- According to IQVIA, Jynarque had estimated annual U.S. sales of \$1.5 billion ending December 2024.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.